Fax: (410) 955-0833
Neoadjuvant gemcitabine and cisplatin: Another step on the path toward improving the outcomes of patients with high-risk, invasive bladder cancer†
Article first published online: 29 SEP 2008
Copyright © 2008 American Cancer Society
Volume 113, Issue 9, pages 2379–2381, 1 November 2008
How to Cite
Nielsen, M. E. (2008), Neoadjuvant gemcitabine and cisplatin: Another step on the path toward improving the outcomes of patients with high-risk, invasive bladder cancer. Cancer, 113: 2379–2381. doi: 10.1002/cncr.23849
See referenced original article on pages 2471–7, this issue.
- Issue published online: 17 OCT 2008
- Article first published online: 29 SEP 2008
- Manuscript Accepted: 27 MAY 2008
- Manuscript Received: 21 MAY 2008
Until such time as there are data from prospective randomized trials directly comparing neoadjuvant cisplatin and gemcitabine (GC) to neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin, the data presented in the study by Dash et al in this issue of Cancer provide strong support for the consideration of neoadjuvant GC as an effective and well-tolerated component in the armamentarium against high-risk bladder cancer.